Company news

Towa Pharmaceutical Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

(Change in Disclosure Information) Notice of Change in the Date of Execution of the Share Transfer Concerning the Acquisition of Shares

October 30, 2026

FY2026(1st quarter) Briefing Script and Q&A Summary of financial results meeting(319K／15P)

September 1, 2026

Consolidated Financial Results for the Three Months Ended June 30, 2026 (Based on Japanese GAAP)

August 6, 2026

Notice of Completion of Payment for the Issuance of 1st Series Class A Preferred Shares through Third-Party Allotment

July 31, 2026

Notice of Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation

July 10, 2026

Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. and Transfer of Manufacturing and Marketing Approvals

July 3, 2026

Notice of Changes in Officers

June 24, 2026

FY2025 Briefing Script and Q&A Summary of financial results meeting(581K／27P)

June 16, 2026

FY2025 Supplementary Material of Financial Results(1.0M／46P)

May 14, 2026

FY2025 Consolidated Financial Results for the Year Ended March 31, 2026(Based on Japanese GAAP) (224K／22P)

May 14, 2026

FY2025(3rd quarter) Briefing Script and Q&A Summary of financial results meeting(296K／17P)

March 18, 2026

FY2025(3rd quarter) Supplementary Material of Financial Results(701K／24P)

February 13, 2026

FY2025(3rd quarter) Consolidated Financial Results for the Nine Months Ended December 31, 2025(Based on Japanese GAAP) (182K／13P)

February 13, 2026

FY2025(2nd quarter) Briefing Script and Q&A Summary of financial results meeting(297K／16P)

December 25, 2025

FY2025(2nd quarter) Supplementary Material of Financial Results(377K／26P)

November 10, 2025

FY2025(2nd quarter) Consolidated Financial Results for the Six Months Ended September 30, 2025(Based on Japanese GAAP) (403K／12P)

November 10, 2025

FY2025(1st quarter) Supplementary Material of Financial Results(922K／23P)

August 7, 2025

FY2025(1st quarter) Consolidated Financial Results for the Three Months Ended June 30, 2025(Based on Japanese GAAP) (311K／12P)

August 7, 2025

Notice of the 69th Ordinary General Meeting of Shareholders

May 29, 2025

FY2024 Supplementary Material of Financial Results (1.3M／44P)

May 15, 2025

FY2024(4th quarter) Consolidated Financial Results for the Year Ended March 31, 2025(Based on Japanese GAAP) (416K／18P)

May 15, 2025

FY2024(3rd quarter) Consolidated Financial Results for the Nine Months Ended December 31, 2024(Based on Japanese GAAP) (416K／13P)

February 13, 2025

FY2024(3rd quarter) Supplementary Material of Financial Results(994K／28P)

February 13, 2025

FY2024(2nd quarter) Supplementary Material of Financial Results(523K／36P)

November 12, 2024

FY2024(2nd quarter) Consolidated Financial Results for the Six Months Ended September 30, 2024(Based on Japanese GAAP) (467K／13P)

November 12, 2024

FY2023(1st quarter) Summary of Consolidated Financial Results for the Three Months Ended June 30, 2023(Based on Japanese GAAP) (375K/7P)

August 10, 2023

FY2023(1st quarter) Supplementary Material of Financial Results (1.03M/28P)

August 10, 2023

Notice of the 67th Ordinary General Meeting of Shareholders （176KB／10P）

May 30, 2023

FY2022 Supplementary Material of Financial Results (1.2M/42P)

May 15, 2023

FY2022(4th quarter) Summary of Consolidated Financial Results for the Year Ended March 31, 2023(Based on Japanese GAAP) (616K/10P)

May 15, 2023

Towa Pharmaceutical: Breckenridge Pharmaceutical, Inc. - Towa completes acquisition of Esteve's Generic Division

February 3, 2020

Decks

The 5 newest of 73 decks. Every deck is listed under its year.